Last reviewed · How we verify
Sinemet (comparator)
Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa.
Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa. Used for Parkinson's disease, Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication.
At a glance
| Generic name | Sinemet (comparator) |
|---|---|
| Also known as | Long acting levodopa, Sinemet CR 250' (Levodopa 200mg, and 50mg carbidopa), Levodopa, IR CD-LD Tablets, carbidopa/levodopa |
| Sponsor | XenoPort, Inc. |
| Drug class | Dopamine precursor with peripheral decarboxylase inhibitor |
| Target | Aromatic L-amino acid decarboxylase (AADC); dopaminergic system |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa is converted to dopamine in the brain to replace depleted dopamine in Parkinson's disease. Carbidopa inhibits the enzyme aromatic L-amino acid decarboxylase in the periphery, preventing premature conversion of levodopa to dopamine outside the brain, thereby increasing the amount of levodopa available to cross the blood-brain barrier and reducing peripheral side effects.
Approved indications
- Parkinson's disease
- Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication
Common side effects
- Dyskinesia
- Motor fluctuations
- Nausea
- Dizziness
- Orthostatic hypotension
- Hallucinations
- Confusion
Key clinical trials
- A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects (PHASE1)
- Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study (PHASE4)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects (PHASE2)
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). (PHASE3)
- Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity (PHASE2)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa (PHASE2)
- Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinemet (comparator) CI brief — competitive landscape report
- Sinemet (comparator) updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI